Trial Profile

A Phase 2a placebo-controlled clinical trial of intranasal foralumab for the treatment of Long COVID

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Foralumab (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

26 Apr 2023 According to the Tiziana Life Sciences media release, the company expects to file IND in the second quarter of 2023.
19 Apr 2023 New trial record
13 Apr 2023 According to the Tiziana Life Sciences media release, after refining clinical protocols, the company need to discuss the approach with the FDA and plan to file an IND in 4Q 2023, company will anticipated to start this study based upon successful feedback from the FDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com